Cellectar Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary

Cellectar Biosciences

13/08/2026 14:31

Cellectar Biosciences Inc CLRB.OQ reported a quarterly adjusted loss of 57 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-3.39.  The mean expectation of three analysts for the quarter was for a loss of 48 cents per share. Wall Street expected results to range from -64 cents to -34 cents per share.
Reported revenue was zero​; analysts expected zero. 
Cellectar Biosciences Inc's reported EPS for the quarter was a loss of 57 cents​.
The company reported a quarterly loss of $6.93 million.
Cellectar Biosciences Inc shares had fallen by 6.5% this quarter and lost 11.9% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 19.3% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" 
Wall Street's median 12-month price target for Cellectar Biosciences Inc is $10.00, about 74% above its last closing price of $2.60
This summary was machine generated from LSEG data August 13 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.48
-0.57
Missed
Mar. 31 2026 
-1.88
-1.30
Beat
Dec. 31 2025 
-2.29
-1.29
Beat
Sep. 30 2025 
-2.53
-1.41
Beat